The National Neuroscience Institute (NNI) is testing the substance, which is currently already available in a pill form. NNI signed a Memorandum of Understanding (MOU) with Malaysian pharmaceutical company Hovid Berhad to test whether palm tocotrienol – extracted from crude palm oil – works in experimental models of Parkinson’s disease. Clinical studies will be carried out subsequently.
“Our short- to mid-term plan is to come up with a drug to delay the onset of Parkinson’s for those at risk of the disease,” said Professor Tan Eng King, NNI’s Director of Research.
